Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aimed to assess the efficacy of cryotherapy in controlling Peripheral Neuropathy in cancer children
Peripheral neuropathy is a serious condition characterized by symmetrical, distal damage to the peripheral nerves that may be caused by several classes of drugs, including chemotherapeutic agents. Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect estimated to occur in up to 40% of patients undergoing chemotherapy, with its incidence increasing in patients being treated with multiple agents. Pharmacists play a pivotal role in the prevention and management of CIPN by recommending evidence-based pharmacologic and non pharmacologic strategies appropriate for the individual patient.Peripheral neuropathy (PN) is a systemic disease characterized by symmetrical, distal damage to the peripheral nerves that negatively impacts patient quality of life (QOL). Prolonged symptoms associated with PN can cause pain, interfere with functional ability (e.g., dressing, driving, house-work), and disrupt emotional health.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| the study group | Experimental | Cryotherapy (apparatus) |
|
| the control group | No Intervention | not received cryotherapy |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cryotherapy | Device | Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists |
| Measure | Description | Time Frame |
|---|---|---|
| Nerve conduction studies (NCS) | nerve conduction velocity for sensory ulnar nerve | nerve conduction velocity for sensory ulnar nerve at day 0 |
| Nerve conduction studies (NCS) | nerve conduction velocity for sensory ulnar nerve | nerve conduction velocity for sensory ulnar nerve at day 90 |
| Nerve conduction studies (NCS) | nerve conduction velocity for sensory median nerve | nerve conduction velocity for sensory sensory median nerve at day 0 |
| Nerve conduction studies (NCS) | nerve conduction velocity for sensory median nerve | nerve conduction velocity for sensory sensory median nerve at day 90 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Walaa E Heneidy, PHD | Contact | +20127512697 | walaa.eldesoukey@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Nehad A. Abo-zaid, PHD | South Valley University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| South Valley University, Faculty of Physical Therapy | Qina | 83523 | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017679 | Cryotherapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Single (Outcomes Assessor) Blinding process to participants and care providers was impossible due to the nature of intervention therapy. Data were analyzed by an impartial statistician (outcomes assessor), referring to each arm with an encoded name: Group A (control group) and Group B (study group).
|